Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480407 | 0.94 | GSK3B (0.53) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6478320 | 0.93 | GSK3B (0.52) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6478405 | 0.91 | GSK3B (0.50) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6486769 | 0.89 | GSK3B (0.60) | GSK3BDGAT1 | |
| SCHEMBL6478200 | 0.88 | GSK3B (0.48) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6478528 | 0.88 | GSK3B (0.48) | GSK3BDGAT1ALDH1A1RAB9AMEN1 | |
| SCHEMBL6479160 | 0.88 | GSK3B (0.57) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL6490313 | 0.88 | GSK3B (0.47) | GSK3BDGAT1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1461458 | 0.84 | GSK3B (0.48) | GSK3BALDH1A1SMN1; SMN2KDM4EATM | |
| SCHEMBL1462471 | 0.83 | GSK3B (0.49) | GSK3BDGAT1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4648630-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| JP-2005530711-A | — | — | 2005-10-13 | — | — | JP | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| EP-1487804-A2 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
| WO-2003078403-A2 | DERIVES D’AMINOINDAZOLES COMME INHIBITEURS DE PROTEINE-KINASE | AVENTIS PHARMA S.A. (FR) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | GSK3B 2342/4885DGAT1 4335/4885ALDH1A1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.